Nucleus RadioPharma has secured $56 million in a Series A funding round to expand production of radiopharmaceutical treatments for cancer patients.
Led by by Eclipse and GE HealthCare, the investment will help the company accelerate research, streamline supply chains, and make targeted radiopharmaceutical therapies accessible, the company said. Other investors included Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and the University of Missouri.
Nucleus RadioPharma is a contract development and manufacturing organization (CDMO) launched last year aiming to establish itself as a leading CDMO in the area of targeted radiotherapies and theranostics.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
